抗氧化剂ebselen 对SHRsp 冠状动脉eNOS 蛋白表达的影响

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (2): 141-144.

抗氧化剂ebselen 对SHRsp 冠状动脉eNOS 蛋白表达的影响

隋辉, 王文, 王佩合, 李悦

中国医学科学院中国协和医科大学阜外心血管病医院, 心血管病研究所, 北京100037

收稿日期:2004-12-08 修回日期:2005-01-27 出版日期:2005-02-06 发布日期:2020-11-18
通讯作者: 王文, 男, 教授, 博士生导师, 主要从事心血管病研究。Tel:010-68351990 E-mail:wangwu@pulic.bta.net.cn
作者简介:隋辉, 女, 博士研究生, 主要从事高血压病研究。Tel:010-88362426 E-mail:suihuipumc@sina.com.

Effects of antioxidant ebselen (PZ51) on eNOS protein expression of coronary artery in SHRsp

SUI Hui, WANG Wen, WANG Pei-he, LI Yue

Institute of Cardiovascular, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China

Received:2004-12-08 Revised:2005-01-27 Online:2005-02-06 Published:2020-11-18

摘要/Abstract

摘要： 目的:研究新型抗氧化剂含硒谷胱甘肽过氧化物酶模拟物PZ51 对卒中易感型自发性高血压大鼠(SHRsp) 高血压发展的慢性过程中冠状动脉内皮型一氧化氮合成酶(eNOS) 表达的影响。方法:22 只8 周龄SHRsp 随机分为PZ51 组和对照组, 灌胃治疗6 周。测量心脏重量比值、心脏结构;采用分光光度计测心肌组织匀浆一氧化氮(NO) 的浓度;免疫组化检测冠状动脉eNOS 蛋白表达。结果:PZ51 组较对照组心肌组织匀浆NO 浓度显著升高(1.18±0.25vs 0.72±0.18 μmol°mg^-1 prot, P<0.05)、冠状动脉内皮eNOS 蛋白表达显著增加(7.45±2.10 vs 2.77±2.07, P<0.05) 。结论:PZ51 治疗6 周显著增加了SHRsp 冠状动脉eNOS 蛋白表达及心肌组织NO的水平。

关键词: PZ51, SHRsp, 内皮型一氧化氮合成酶, 冠状动脉

Abstract: AIM: To investigate the effects of new antioxidant, seleno-Glutathione peroxidase PZ51 on endothelial nitric oxide synthase (eNOS) protein expression of coronary artery in Stroke-Prone Spontaneously Hypertensive rat (SHRsp) during the chronic process of hypertension.METHODS: 22 SHRsp of 8-week-old which were randomly divided into PZ51 group and control group were administered by gavage for six weeks.Heart weight ratio, heart structure, the level of nitric oxide (NO) of myocardium and eNOS protein of coronary artery was examined. RESULTS: Compared with the control group, PZ51 significantly increased NO of myocardium homogenate (1.18±0.25 vs 0.72±0.18 μmol°mg^-1 prot, P<0.05) and eNOS protein expression (7.45±2.10 vs 2.77±2.07, P<0.05) of coronary artery.CONCLUSION: After 6 weeks administration of PZ51, the eNOS protein expression of coronary artery and NO level of myocardium in SHRsp significantly increased.

Key words: PZ51, SHRsp, endothelial nitric oxidesynthase, coron aryartery

中图分类号:

R966

隋辉, 王文, 王佩合, 李悦. 抗氧化剂ebselen 对SHRsp 冠状动脉eNOS 蛋白表达的影响[J]. 中国临床药理学与治疗学, 2005, 10(2): 141-144.

SUI Hui, WANG Wen, WANG Pei-he, LI Yue. Effects of antioxidant ebselen (PZ51) on eNOS protein expression of coronary artery in SHRsp[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(2): 141-144.

参考文献

1 Liao JK, Shin WS, Lee WY, Clark SL.Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase[J].J Biol Chem, 1995;270:319-24
2 Schachinger V, Britten MB, Zeiher AM.Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease[J].Circulation, 2000;101:1899-906
3 Sibel U, Pascal P, Mckeown, Ulvi B.Vitamins reverse endothelial dysfunction tnrough regulation of eNOS and NAD(P) H oxidase activities[J].Hypertens, 2003;41:534-9
4 Chen X, Touyz RM, Park JB, Schiffrin EL.Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR[J].Hypertension, 2001;38:606-11
5 Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A.Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension[J].Circulation, 1998;97:2222-9
6 Bradford MM.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding[J].Anal Biochem, 1976;72:248-54
7 Laude K, Favre J, Thuillez C, Richard V.NO produced by endothelial NO synthase is a mediator of delayed preconditioninginduced endothelial protection[J].Am J Physiol Heart Circ Physiol, 2003;284:H2053-60
8 Bayraktutan U.Nitric oxide synthase and NAD(P) H oxidase modulate coronary endothelial cell growth[J].JMol Cell Cardiol, 2004;36:277-86
9 Karine L, Julie F, Christian T, Vincent R.NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection[J].Am J Physiol Heart Circ Physiol, 2003;284:H2053-60
10 Bell RM, Yellon DM.The contribution of endothelial nitric oxide synthase to early ischaemic preconditioning:the lowering of the preconditioning threshold, an investigation in eNOS knockout mice[J].Cardiovasc Res, 2001;52:274-80
11 Sumeray MS, Rees KK, Yellon DM.Infarct size and nitric oxide synthase in murine myocardium[J].J Mol Cell Cardiol, 2000;32:35-42
12 Fukuo K, Yang J, Suzuki T, Kaimoto T, Takemura Y, Yasuda O, et al.Nifedipine upregulates manganese superoxide dismutase expression in vascular smooth muscle cells via endothelial cell-dependent pathways[J].Hypertens Res, 2003;26:503-8
13 Fukai T, Siegfried MR, Ushio-Fukai M, ChengY, Kojda G, Harrison DG.Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training[J].J Clin Invest, 2000;105, 1631-9
14 NilanjanaM, Tetsuya Y, Dipak KD.Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis [J].Free Radical Biology Medicine, 1998;24:869-75
15 Tousoulis D, Antoniades C, Tentolouris C, L-arginine in cardiovascular disease:dream or reality[J].Vasc Med, 2002;7: 203-11
16 Kobay ashi N, Kobayashi K, Hara K, Higashi T, Yanaka H, Yagi S, et al.Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats[J].Am J Hypertens, 1999;12:483-91
17 Lenasi H, Kohlstedt K, Fichtlscherer B, Mulsch A, Busse R, Fleming I.Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495 [J].Cardiovasc Res, 2003;59:844-53
18 Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, et al.Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase akt pathway[J].J Cardiovasc Pharmacol, 2004;44:348-55
19 Birnbaum Y, Ashitkov T, Uretsky BF, Ballinger S, Motamedi M.Reduction of infarct size by short-term pretreatment with atorvastatin[J].Cardiovasc Drugs Ther, 2003;17:25-30
20 Wolfrum S, Grimm M, Heidbreder M, Dendorfer A, Katus HA, Liao JK, et al.Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme a reductase inhibitor is mediated by endothelial nitric oxide synthase[J].J Cardiovasc Pharmacol, 2003;41:474-80
21 Nadruz WJR, Lagosta VJ, Moreno H, JrCoelho OR, Franchini KG.Simvastatin prevents load-induced protein tyrosine nitration in overloaded hearts[J].Hypertension, 2004;43:1060-6

[1]	钱锦, 王峰岩. 老年急性心肌梗死患者PCI术后血清NT-proBNP水平的影响因素并分析其对近期预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(6): 658-665.
[2]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[3]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[4]	方秋珏, 王昭军, 袁伟, 丁澍, 王中群. 可溶性ST2与冠脉复杂病变及其严重程度的相关性[J]. 中国临床药理学与治疗学, 2021, 26(3): 278-284.
[5]	李亚男，陈志武，郭岩. 映山红花总黄酮阻断Rho激酶促进大鼠冠状动脉舒张作用的机制[J]. 中国临床药理学与治疗学, 2019, 24(12): 1353-1357.
[6]	刘莹，邵军进，孙大新. 地氟烷复合右美托咪定对不停跳冠状动脉搭桥术（OPCABG）患者的疗效分析[J]. 中国临床药理学与治疗学, 2018, 23(4): 440-445.
[7]	韦喻镪. 利拉鲁肽对急性心肌梗死PCI术后心肌的保护作用[J]. 中国临床药理学与治疗学, 2018, 23(2): 184-188.
[8]	刘长江，武洋，邵培培，李少华，程路峰. 游泳力竭对冠脉结扎致大鼠慢性心衰模型的优化[J]. 中国临床药理学与治疗学, 2017, 22(12): 1340-1345.
[9]	王世奇，胡烨文，陈晓敏，王健，叶红华 . 不同强度华法林在冠状动脉粥样硬化性心脏病并发心房颤动患者中的效果对比[J]. 中国临床药理学与治疗学, 2017, 22(12): 1410-1414.
[10]	张宁汝，张恒，李妙男，孙强，王洪巨，汤阳. 高血压合并急性冠脉综合征患者P₄₅₀2C19基因多态性与氯吡格雷抵抗及冠状动脉介入术后近期预后关系探讨[J]. 中国临床药理学与治疗学, 2016, 21(4): 425-431.
[11]	许骥，华琦，郝恒剑，徐东，胡少东，李博宇，刘志，桑成，夏经钢. 术前强化他汀治疗联合碘克沙醇对70岁以上患者PCI术后肾功能的保护作用[J]. 中国临床药理学与治疗学, 2016, 21(1): 82-86.
[12]	周逸, 陈曼华, 何琴, 陈刚, 黄婷, 张辉. 不同强度阿托伐他汀对冠脉斑块作用的比较[J]. 中国临床药理学与治疗学, 2015, 20(8): 938-942.
[13]	章霞, 柯永胜. 新型P2Y12受体抑制剂替格瑞洛临床研究进展[J]. 中国临床药理学与治疗学, 2014, 19(4): 459-464.
[14]	刘艳, 杨解人, 郝伟, 张俊秀, 唐丽娟, 陈国祥. 复方山菊对自发性高血压大鼠主动脉损伤的保护作用及机制[J]. 中国临床药理学与治疗学, 2013, 18(7): 732-737.
[15]	贾亮亮, 柯永胜. 急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗凝策略[J]. 中国临床药理学与治疗学, 2013, 18(4): 469-475.